FKBP1A
ENSG00000088832
Target class
Enzyme
Chromosome
20
Approved drugs
5
Clinical candidates (approved and in development)
7
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- FKBP1A
- Gene name
- FKBP prolyl isomerase 1A
- Gene symbol
- FKBP1A
- Previous gene symbols
- FKBP1
- Protein name
- Peptidyl-prolyl cis-trans isomerase FKBP1A (PPIase FKBP1A) (EC 5.2.1.8) (12 kDa FK506-binding protein) (12 kDa FKBP) (FKBP-12) (Calstabin-1) (FK506-binding protein 1A) (FKBP-1A) (Immunophilin FKBP12) (Rotamase)
- FKBP-12
- FKBP12
- PKC12
- PPIASE
- FKBP12C
- Gene biotype
- Protein coding
- Gene family
- FKBP prolyl isomerase family|MicroRNA protein coding host genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 437.19
- Tissue specificity (Gini)
- 0.262
- Tissue specificity (tau)
- 0.647
- KEGG gene identifiers
- hsa:2280
- Protein interaction confidence
- 0.821213
- Protein interaction partners
- 75
- R-HSA-166208
- R-HSA-2025928
- R-HSA-2173789
- R-HSA-2173791
- R-HSA-3656535
- R-HSA-9679191
- R-HSA-9692916
- End position
- 1393164
- Start position
- 1368977
- Chromosome
- 20
- Strand
- Reverse
- Cytoplasm, cytosol . Sarcoplasmic reticulum membrane
- Peripheral membrane protein
- Cytoplasmic side .
- Cytosol
- Golgi apparatus
Publication evidence
- PubMed 1701173
- Tissue specificity (tau)
- 0.647288
- Expression inequality (Gini)
- 0.262453
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 437.19
- Lung
- 317.27
- Brain - Nucleus accumbens (basal ganglia)
- 305.23
- Adipose - Visceral (Omentum)
- 304.8
- Thyroid
- 284.35
Expression in transcripts per million
- Cells - Cultured fibroblasts437.19
- Lung317.27
- Brain - Nucleus accumbens (basal ganglia)305.23
- Adipose - Visceral (Omentum)304.8
- Thyroid284.35
- Adipose - Subcutaneous272.99
- Cells - EBV-transformed lymphocytes252.03
- Uterus245.28
- Spleen219.48
- Breast - Mammary Tissue214.13
- Brain - Caudate (basal ganglia)212.12
- Artery - Coronary199.8
- Artery - Aorta191.28
- Cervix - Endocervix186.8
- Fallopian Tube184.55
- Ovary181.74
- Nerve - Tibial181.52
- Cervix - Ectocervix181.01
- Vagina169.56
- Esophagus - Mucosa168.82
- Whole Blood168.02
- Brain - Frontal Cortex (BA9)167.19
- Artery - Tibial165.91
- Bladder165.84
- Prostate158.12
And 29 more, listed on the interactive page.
- GO:0006458
- GO:0014809
- GO:0030512
- GO:0032880
- GO:0032926
- GO:0042026
- GO:0043123
- GO:0050776
- GO:0051604
- GO:0097435
- GO:1902991
- GO:1990000
- GO:0005737
- GO:0005829
- GO:0016020
- GO:0030018
- GO:0003755
- GO:0005160
- GO:0005246
- GO:0005515
- GO:0005528
- GO:0030547
- GO:0034713
- GO:0044325
- GO:0070411
- GO:0070697
Related records
Trials (2,587)
- 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
- 10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
- 10-Years Follow-up of the EXAMINATION Trial
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
- 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
- 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
- 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
- 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
- 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
- A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
- A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
- A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
- A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
- A Blood Stem Cell Transplant for Sickle Cell Disease
Drugs (8)
- Everolimus FK506-binding protein 1A inhibitor
- Olocrolimus FK506-binding protein 1A inhibitor
- Pimecrolimus FK506-binding protein 1A inhibitor
- Sirolimus FK506-binding protein 1A inhibitor
- Tacrolimus FK506-binding protein 1A inhibitor
- Tacrolimus anhydrous FK506-binding protein 1A inhibitor
- Temsirolimus FK506-binding protein 1A inhibitor
- Zotarolimus FK506-binding protein 1A inhibitor